Pharmacokinetics of Caffeine in Patients with Decompensated Type I and Type II Diabetes Mellitus

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1991 Jan 1

PMID 1761072

Citations 2

Authors

T Zysset

H Wietholtz

Affiliations

Soon will be listed here.

Abstract

Diabetes may alter the pharmacokinetics of aminopyrine and antipyrine, which are used to assess liver function. Caffeine has recently been used to test liver function, but the effect of diabetes on caffeine kinetics is not known. The kinetics of caffeine has been examined in patients with decompensated Type I and Type II diabetes and in two age- and sex-matched control groups. In both types of diabetes the apparent caffeine clearance, half-life, and apparent volume of distribution were similar to controls. It is concluded that decompensated diabetes does not influence the cytochrome P-448 mono-oxygenase system responsible for caffeine metabolism.

Citing Articles

Development of a Physiologically Based Pharmacokinetic Population Model for Diabetic Patients and its Application to Understand Disease-drug-drug Interactions.

Li Y, Li X, Zhu M, Liu H, Lei Z, Yao X Clin Pharmacokinet. 2024; 63(6):831-845.

PMID: 38819713 DOI: 10.1007/s40262-024-01383-2.

Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Dostalek M, Akhlaghi F, Puzanovova M Clin Pharmacokinet. 2012; 51(8):481-99.

PMID: 22668340 DOI: 10.2165/11631900-000000000-00000.

References

Daintith H, Stevenson I, OMalley K . Influence of diabetes mellitus on drug metabolism in man. Int J Clin Pharmacol Biopharm. 1976; 13(1):55-8. View

Vesell E . The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther. 1979; 26(3):275-86. DOI: 10.1002/cpt1979263275. View

Past M, Cook D . Effect of diabetes on rat liver cytochrome P-450. Evidence for a unique diabetes-dependent rat liver cytochrome P-450. Biochem Pharmacol. 1982; 31(20):3329-34. DOI: 10.1016/0006-2952(82)90569-x. View

Schnegg M, Lauterburg B . Quantitative liver function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. J Hepatol. 1986; 3(2):164-71. DOI: 10.1016/s0168-8278(86)80022-8. View

Wahllander A, Renner E, Preisig R . Fasting plasma caffeine concentration. A guide to the severity of chronic liver disease. Scand J Gastroenterol. 1985; 20(9):1133-41. DOI: 10.3109/00365528509088884. View

Bonati M, Latini R, Galletti F, Young J, Tognoni G, Garattini S . Caffeine disposition after oral doses. Clin Pharmacol Ther. 1982; 32(1):98-106. DOI: 10.1038/clpt.1982.132. View

JOST G, Wahllander A, von Mandach U, Preisig R . Overnight salivary caffeine clearance: a liver function test suitable for routine use. Hepatology. 1987; 7(2):338-44. DOI: 10.1002/hep.1840070221. View

Teunissen M, Spoelstra P, Koch C, Weeda B, van Duyn W, Janssens A . Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. Br J Clin Pharmacol. 1984; 18(5):707-15. PMC: 1463543. DOI: 10.1111/j.1365-2125.1984.tb02533.x. View

Hepner G, Vesell E . Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med. 1974; 291(26):1384-8. DOI: 10.1056/NEJM197412262912605. View

10.

CAMPBELL M, Grant D, Inaba T, KALOW W . Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos. 1987; 15(2):237-49. View

11.

Wietholtz H, Voegelin M, Arnaud M, BIRCHER J, Preisig R . Assessment of the cytochrome P-448 dependent liver enzyme system by a caffeine breath test. Eur J Clin Pharmacol. 1981; 21(1):53-9. DOI: 10.1007/BF00609588. View

12.

ANDREASEN P, Greisen G . Phenazone metabolism in patients with liver disease. Eur J Clin Invest. 1976; 6(1):21-6. DOI: 10.1111/j.1365-2362.1976.tb00489.x. View

13.

BIRCHER J, Kupfer A, Gikalov I, Preisig R . Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther. 1976; 20(4):484-92. DOI: 10.1002/cpt1976204484. View

14.

Wietholtz H, Zysset T, Kreiten K, Kohl D, Buchsel R, Matern S . Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol. 1989; 36(4):401-6. DOI: 10.1007/BF00558303. View

15.

Parsons W, NEIMS A . Effect of smoking on caffeine clearance. Clin Pharmacol Ther. 1978; 24(1):40-5. DOI: 10.1002/cpt197824140. View

16.

Desmond P, Patwardhan R, Johnson R, Schenker S . Impaired elimination of caffeine in cirrhosis. Dig Dis Sci. 1980; 25(3):193-7. DOI: 10.1007/BF01308138. View

17.

Melani F, Rubenstein A, Oyer P, Steiner D . Identification of proinsulin and C-peptide in human serum by a specific immunoassay. Proc Natl Acad Sci U S A. 1970; 67(1):148-55. PMC: 283181. DOI: 10.1073/pnas.67.1.148. View

18.

Zysset T, Wahllander A, Preisig R . Evaluation of caffeine plasma levels by an automated enzyme immunoassay (EMIT) in comparison with a high-performance liquid chromatographic method. Ther Drug Monit. 1984; 6(3):348-54. DOI: 10.1097/00007691-198409000-00016. View

19.

Zysset T, Sommer L . Diabetes alters drug metabolism--in vivo studies in a streptozotozin-diabetic rat model. Experientia. 1986; 42(5):560-2. DOI: 10.1007/BF01946703. View

20.

Webb P, Bonser A . Basal C-peptide in the discrimination of type I from type II diabetes. Diabetes Care. 1981; 4(6):616-9. DOI: 10.2337/diacare.4.6.616. View